Proactive Investors - Run By Investors For Investors

ImmuPharma drug needs further analysis; it could still have a role in treating lupus – City analyst

“We need to see more data,” said Northland Capital's Vadim Alexandre. “There is a major unmet medical"
test tubes
The reaction to the clinical trial was described as knee-jerk

ImmuPharma PLC's (LON:IMM) drug Lupuzor needs further analysis and certainly isn’t a bust, according to Vadim Alexandre, analyst at Northland Capital.

With shares down sharply on Tuesday, the reaction to phase III trial results for the lupus drug has been “knee-jerk” and probably not fully reflective of the outlook for the treatment, he said in an interview with Proactive’s Andrew Scott.

The readout from the study showed Lupuzor didn’t have a statistically significant impact on patients compared with the placebo plus the standard of care.

WATCH: Immupharma PLC still confident on Lupuzor's future

However, there are two points to grasp, Alexandre said. First, patients responded particularly well to the placebo plus standard of care because the cortical steroids worked. Second, the drug actually worked well in certain patient groups.

READ: Today's news

“We need to see more data,” Alexandre said. “There is a major unmet medical need and there has only been one drug out in the market in the last 50 years and that itself is not a perfect drug.”

On the news ImmuPharma is talking to potential partners, the Northland analyst added: “The primary end-point has not been met, but I think they will be looking at what the possibilities are for doing further and future trials.”


View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

A stomach adenocarcinoma
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use